Filipa Gouveia

Filipa Gouveia

Auto-generated profile, based on publicly available information

Filipa Gouveia

Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
JGJoana Gonçalves
Joana Gonçalves
Joana BickerJoana Bicker
Joana Bicker
FGFilipa Gouveia
Filipa Gouveia
JLJoana Liberal
Joana Liberal
RORui Caetano Oliveira
Rui Caetano Oliveira
Ana FortunaAna Fortuna
Ana Fortuna

1 March 2020 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
FGFilipa Gouveia
Filipa Gouveia
Joana BickerJoana Bicker
Joana Bicker
JSJoana Santos
Joana Santos
MRMarília Rocha
Marília Rocha
Gilberto AlvesGilberto Alves
Gilberto Alves
Ana FortunaAna Fortuna
Ana Fortuna

1 October 2019 in Analytica Chimica Acta
Verified
Journal Article
Open access
FGFilipa Gouveia
Filipa Gouveia
Joana BickerJoana Bicker
Joana Bicker
JGJoana Gonçalves
Joana Gonçalves
Gilberto AlvesGilberto Alves
Gilberto Alves
AFAmílcar Falcão
Amílcar Falcão
Ana FortunaAna Fortuna
Ana Fortuna
Direct oral anticoagulants (DOACs) are first-line drugs used for the treatment of venous thromboembolism and prevention of stroke in patients with atrial fibrillation. These drugs do not require the regular biochemical monitoring that is mandatory for warfarin, and they exhibit shorter half-lives and have a faster onset of action. Since recent real-world studies evidence a higher prevalence of adverse side effects than what was anticipated in clinical trials, monitoring the plasma concentrations of DOACs is being used to personalize their pharmacotherapy, in accordance to the characteristics of the patient, and to evaluate the adherence to therapy. In order to fulfill the aforementioned clinical unmet needs, there are specific coagulation assays that indirectly assess the plasma concentrations of DOACs. Nevertheless, these assays are not sufficiently accurate or sensitive. For this reason, liquid chromatography techniques coupled to mass spectrometry detection, are considered the gold standard method to accurately determine plasma concentrations of DOACs. Therefore, the present paper provides the first comprehensive review of the current analytical methods that were developed and validated for the quantitative determination of apixaban, dabigatran, rivaroxaban and/or edoxaban and their main metabolites in biological samples. The chromatographic methods will be particularly highlighted and an emphasis will be placed on the major difficulties faced during optimization and development steps. In addition, the physicochemical, pharmacokinetic and pharmacodynamic characteristics of each drug will be critically related to chromatographic conditions. Their influence on the pre-treatment procedures and storage conditions of DOACs will be examined, suggesting strategies that should be applied to accurately quantify DOACs in biological samples.

9 January 2024 in International Immunopharmacology
Verified
Journal Article
Open access
FGFilipa Gouveia
Filipa Gouveia
CFCarla Fonseca
Carla Fonseca
ASAna Silva
Ana Silva
ACAntoni Camins
Antoni Camins
MCM. Teresa Cruz
M. Teresa Cruz
Ana FortunaAna Fortuna
Ana Fortuna
New strategies are urgently needed to manage and delay the development of Alzheimer's disease (AD). Neuroinflammation is a significant contributor to cognitive decline in neurodegenerative diseases, including AD. Angiotensin receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACEIs) protect hypertensive patients against AD, but the cellular and molecular mechanisms underlying these effects remain unknown. In light of this, the protective effects of three ARBs and three ACEIs against neuroinflammation and cognitive decline were investigated through comprehensive pharmacologicalin vitro/in vivoscreening. BV-2 microglia cells were exposed tolipopolysaccharide (LPS) and treated with ARBs and ACEIs to provide initial insights into the anti-inflammatory properties of the drugs. Subsequently, irbesartan was selected, and its efficacy was evaluated inC57/BL6 male miceintranasally administered with irbesartan and injected with LPS. Long-term memory and depressive-like behavior were evaluated; dendritic spines were measured as well as neuroinflammation, neurodegeneration and cognitive decline biomarkers. Irbesartan mitigated memory loss and depressive-like behavior in mice treated with LPS, probably because itincreased spine density, ameliorated synapsis dysfunction and activated the PI3K/AKT pathway. Irbesartan elevated the levels of hippocampalsuperoxide dismutase2 andglutathione peroxidaseandsuppressed LPS-induced astrogliosis. Overall, this study provides compelling evidence that multiple intranasal administrations of irbesartan can effectively prevent LPS-induced cognitive decline by activating pathways involved in neuroprotection and anti-inflammatory events. These findings underscore the potential of irbesartan as a preventive strategy against the development of AD and other neurodegenerative conditions associated with neuroinflammation.

24 May 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
FGFilipa Gouveia
Filipa Gouveia
MPMarina Carrasco Pérez
Marina Carrasco Pérez
JBJoana Bicker
Joana Bicker
ASAna Silva
Ana Silva
ASArmanda Emanuela Santos
Armanda Emanuela Santos
Ana FortunaAna Fortuna
Ana Fortuna
Alzheimer's disease (AD) involves a complex interplay between amyloid-β plaques, oxidative stress, neuroinflammation and apoptosis, suggesting that multi-target therapies may be more effective than single-target treatments. Angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) have shown protective effects against AD in hypertensive patients. However, those poor blood-brain barrier (BBB) permeability exhibit limited efficacy in neurodegenerative disorders. This study investigated the neuroprotective potential of three ARBs and one ACEI using a combined in vitro and in vivo approach. In N2a and N2a-APPswe cell lines, irbesartan showed the most robust effects, notably increasing p-AKT and HMOX1 levels. Based on these results, irbesartan was selected for the following in vivo studies and administered intranasally (40 mg/kg) to APP/PS1 male mice for 10 weeks. Treated animals showed significant improvements in memory performance, as measured by the novel object recognition test and the Morris water maze. Additionally, irbesartan enhanced dendritic spine density, restored mitochondrial bioenergetics and BBB integrity, and reduced apoptotic markers. These effects were accompanied by a marked reduction in oxidative stress and neuroinflammation. Overall, these results support the potential of intranasal irbesartan as a promising multi-target therapeutic strategy for AD, capable of modulating key pathological features, including synaptic dysfunction, mitochondrial dysfunction, oxidative stress, apoptosis, and neuroinflammation.

3 April 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
CFCarla Fonseca
Carla Fonseca
FGFilipa Gouveia
Filipa Gouveia
TSTânia Soraia Vieira da Silva
Tânia Soraia Vieira da Silva
SCSara Castanheira
Sara Castanheira
LDLeila Driouech
Leila Driouech
Ana FortunaAna Fortuna
Ana Fortuna
Depression is a highly prevalent and incident mental illness. Current pharmacological therapies fail in approximately 30-40% of patients, highlighting the urgent need for novel agents with pleiotropic effects. This preclinical study aimed to identify new antidepressants and cognitive modulators among five phytocannabinoids: cannabichromene, cannabidiol, cannabidivarin, cannabigerol and cannabinol. Phytocannabinoids were first evaluated in BV-2 microglial cells for cell viability and then, for anti-inflammatory activity, where BV-2 cells were previously stimulated with lipopolysaccharide (50 ng/mL). Based on these profiles, and comparing with ketamine, cannabidiol, cannabidivarin and cannabigerol were selected to be administered (55 µmol/kg, i.p.) once to healthy CD-1 male mice, and subsequently, administered six times to mice submitted to the unpredictable chronic mild stress (UCMS) protocol, which is a validated model of depression. Among the phytocannabinoids under investigation, cannabigerol exhibited the lowest cytotoxicity, whereas cannabidiol and cannabidivarin demonstrated the strongest anti-inflammatory effects, significantly reducing nitrite, iNOS and pro-IL1β levels. In healthy mice, only cannabigerol produced consistent antidepressant-like effects in the forced swimming test compared to ketamine. Under UCMS protocol, cannabidivarin was anxiogenic and impaired cognitive and hepatic functions. Cannabidiol, despite its favorable safety profile, failed to ameliorate depressive phenotype or cognitive deficits. Notably, cannabigerol significantly improved cognitive performance, associated with increased dendritic spine density in the hippocampus. Overall, our unprecedented findings demonstrated that a single administration of cannabigerol ameliorates depressive-like behavior in healthy animals, while multiple administrations improved cognitive function in mice exhibiting depressive-like phenotypes. Together, these results highlight the therapeutic potential of cannabigerol in mood and cognitive disorders.